| Name | Title | Contact Details |
|---|
CareCentrix is a leader in managing care to the home. Headquartered in Hartford, Conn., CareCentrix connects patients with the care they need at home, through a national network of over 8,000 credentialed provider locations providers, with customer care centers located across the United States. CareCentrix provides optimal access to quality home care for more than 23 million lives by connecting providers with patients and helping them navigate the complex home care system. CareCentrix`s extensive range of services provides support and coordination for patients and their families in every step of the healing process, including home health, durable medical equipment (DME), home infusion, sleep management and care management services, which ultimately improve care transitions and reduce unnecessary readmissions and emergency room visits.
Adia Information Management Corp. is a Ann Arbor, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Emocha uses video technology and human engagement to empower patients to take every dose of medication as prescribed. emocha facilitates a daily touchpoint for patients in order to expand access to treatment, extend the reach of existing care teams, and retain patients in care. emocha`s turnkey, enterprise adherence solution operates through dose-by-dose observation and clinical assessment of potential administration problems, including technique and side effects. Coupled with daily engagement, support, and incentives, emocha is the first holistic solution to medication non-adherence.
Xenon Pharmaceuticals (NASDAQ:XENE) – a biopharmaceutical company with operations in Vancouver, BC, Canada and Boston, MA, U.S.A. – is committed to delivering innovative medicines to provide a brighter future for patients suffering from neurological disorders. At Xenon, we are advancing an exciting pipeline of neurology-focused therapies, with a particular emphasis on novel treatments for both adult and pediatric patients with epilepsy. XEN496 is currently being evaluated in the Phase 3 “EPIK” clinical trial in young patients with KCNQ2-DEE, a rare and severe form of childhood epilepsy. Late-stage development plans are also underway for our XEN1101 program, building upon the compelling data from the Phase 2b “X-TOLE” study in adult patients with focal epilepsy. We are also proud of the leading-edge science coming out of our discovery labs, with many early-stage research programs underway. In addition to Xenon`s proprietary programs, we have ongoing collaborations with our valued pharmaceutical partners. With a healthy balance sheet to support our growth plans, we continue to build a fully-integrated, premier neuroscience company with strong discovery, development, and commercial operations. Our employees are smart, passionate, dedicated, and driven by their incredibly important work to discover, develop, and deliver new medicines for patients in need. Building and maintaining a respectful, collaborative, inclusive, and productive culture is a priority for us. We are looking for great people who thrive in a fast-paced, dynamic work environment to join our team during this transformative time for Xenon.
Liberty Pacific Medical Imaging is a Signal Hill, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.